ClinicalTrials.gg
RecruitingNCT07472426Updated Mar 16, 2026

Effects of Creatine Supplementation on Cognitive Measures and Markers of Acute Kidney Injury After Exercise in the Heat

An interventional study of Creatine Monohydrate and Maltodextrin (Placebo) in Acute Kidney Injury and Exertional Heat Illness, sponsored by University of Northern Iowa. Recruiting at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-16.

Sponsored by University of Northern Iowa · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 370 studies in Acute Kidney Injury with a site in United States — 72 open to participants now, 88 under way, 9 of them phase 3. Acute Kidney Injury · United States.

Planned enrollment
187th of 237
20 · median 67
Started
2026
with 28 others
No phase
106 of 370
25 open now
Primary completion
2027-03
later than 35 of 87 live
Registered
358th of 370
by date

Among the 370 studies in Acute Kidney Injury with a site in United States, this one is the 187th largest by planned enrollment of the 237 interventional ones that give a count, is one of 29 that started in 2026, is one of 106 with no phase, reaches primary completion later than 35 of the 87 other live ones, and was the 358th registered.

Acute Kidney Injury

1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

72 of the 370 studies in Acute Kidney Injury with a site in United States are open now. Recruiting first, the newest first:

66 more — sign in →

All 72 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 370 studies in Acute Kidney Injury with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if one week of creatine monohydrate supplementation alters inflammation, markers of acute kidney injury (AKI) risk, and cognitive performance in active, young, healthy volunteers. The main questions it aims to answer are:

  1. Does one-week of creatine supplementation alter urinary markers of inflammation (cytokines) during exercise in the heat when compared to placebo?
  2. Does one-week of creatine supplementation alter markers of AKI during exercise in the heat when compared to placebo?
  3. Does one-week of creatine supplementation attenuate reductions in cognitive measures as a response of fatigue from exertional heat stress.

Researchers will compare creatine monohydrate to a placebo (maltodextrin) to see if it alters inflammation, risk of acute kidney injury, and cognition after exercise in the heat.

Participants will :

  • Complete a baseline aerobic exercise test to measure VO2max
  • Ingest 20 grams per day of creatine monohydrate or placebo (maltodextrin) for seven consecutive days
  • Cycle for 90 minutes in a heated chamber (38 C, \~40% relative humidity), alternating low- and high-intensity exercise
  • Self-collect urine before, after, and one-hour after exercise
  • Self-insert a rectal thermistor to measure core temperature
  • Complete cognitive tasks using the NIH toolbox before and after exercise to assess cognition
  • Complete the other condition (placebo or creatine) at least 21 days later
Read the detailed description

The outlined research questions/ hypotheses will require 3 visits (1 baseline, then 2 experimental trials) to the UNI Exercise Physiology Lab.

The first (baseline) visit will involve completing paperwork (informed consent, health history questionnaire, physical activity readiness questionnaire; PAR-Q+), familiarization of cognitive assessment techniques, anthropometric assessments, and a maximal effort, graded exercise test.

Baseline Visit:

- Height and weight will be measured using a standing stadiometer and InBody bioimpedance analyses full body analyzer

  • Baseline/ Familiarization Cognitive Test: The NIH Toolbox Fluid Cognition Battery and Color Word Stroop Test (CWST) will be administered for baseline cognitive values and familiarization. This will be administered via iPad in a quiet room with minimal distractions
  • Cycle Ergometer Test: Aerobic fitness will be assessed using a graded, maximal oxygen consumption test on a cycle ergometer. Subjects will be given a nose clip and mouthpiece which will be connected to a metabolic cart. Heart rate response and gas exchange will be monitored throughout the test.
  • Identification of workloads used for experimental trials: Following the cycle ergometer test, participants will rest in a seated position for 10-minutes. They will then undergo a series of 3-minutes submaximal stages to identify workloads which correspond to an estimated metabolic rate of 4 Watts/ kilogram of body weight (4 W/kg) and 8 W/kg. Watts will be estimated via measuring gas exchange (VO2 and Respiratory exchange ratio). These intensities were chosen as they were the average and peak rates which have been observed in a sample of construction workers during work in the summer.

Exercise Visits (Creatine and Placebo, Visits 2 \& 3):

Each experimental exercise visit consists of supplementation with a standardized breakfast and 90-minutes of exercise on a stationary cycle ergometer located in the heat chamber of the Exercise Physiology Lab. To ensure participant safety and consistency in data collection, the following outlines the environmental conditions, safety considerations, exercise protocols, and measurement procedures that will be followed for each exercise visit.

Environmental Conditions:

All exercise testing will occur in a controlled environmental chamber set to simulate a hot exercise environment. Conditions within the chamber will be maintained at 38 °C (100.4 °F) and 40% relative humidity (WBGT: \~30.2 °C) and monitored continuously via Kestrel Drop temperature and humidity monitoring device.

Supplement Administration:

  1. During the 7 days prior to each exercise visit, the participant will be asked to ingest 20 g/ day of creatine or placebo in a blinded fashion. This will be taken four times per day in 5 grams of supplement ingested with water.
  2. At least one week prior to the trial, a member of the research team will provide the participant with 28 bags of 5 grams of creatine or placebo.

Exercise Visits (visits 2 and 3):

  1. Upon arrival, participants will provide a urine sample for hydration assessment (subjects will collect their own urine sample, in private one-room bathroom located in Exercise Physiology Lab).
  2. Urine Specific Gravity (USG) will be measured using a refractometer following standard procedures to confirm hydration.

    4. Bioelectrical Impedance Analysis: Participants will step on an InBody device which will measure % body fat.

    5. Sleep questionnaire: Participants will be asked to fill out a sleep questionnaire to get an idea if creatine altered sleep quality or duration.

    6. Standardized breakfast, water, and supplement Administration (1 hour prior to exercise)

a. Once adequate hydration is confirmed, participants will consume the assignment supplement (5 grams of creatine or placebo) with a standardized breakfast. After full consumption of food and supplement, the research team will start the 1-hour timer to ensure that a full 60-minutes is waited before starting exercise.

7. After Supplementation but Prior to Exercise:

  1. Cognition: Participants will complete a baseline Color Word Stroop Task and NIH Toolbox Fluid Cognition Battery test via Ipad in quiet and distraction free environment.
  2. Blood Pressure and Blood collection:

i. Participants will sit for 10-minutes. ii. Blood pressure will be recorded and measured. iii. A capillary blood sample will be taken from the earlobe or fingertip to measure blood composition.

c. Urine Collection: In a private restroom, participants will void their bladder into a beaker. Urine will then be stored at -80 °C until later analyses for markers of acute kidney injury.

d. Nude Body Weight: Participants will be instructed to enter a private bathroom to measure nude body weight and self- insert a rectal thermistor to measure core temperature: e. Monitoring Devices: i. Participants will be fitted with a Polar chest-strap that contains a heart rate monitor.

ii. Participants will be fitted with 4, non-invasive skin temperature iButton sensors, placed on the chest, arm, thigh, and leg.

8.Pre-Exercise Baseline Measures

  1. Participants will enter the heat chamber and sit in a chair
  2. While seated, the following baseline measures will be collected:

i. Profile of Mood States (POMS) Questionnaire ii. Color-Word Stroop Test (CWST) (a cognition test) iii. Thermal Comfort \& Strain Scale (TCS) (to understand perceived heat stress) iv. Rating of Perceived Exertion (RPE) v. Heart Rate (HR) and Core Temperature (Tc) vi. Room Temperature and Humidity vii. Visual Analogue Scale for Fatigue (VAS-F) viii. Gastrointestinal Symptoms Questionnaire (GIQ) ix. Environmental Symptoms Questionnaire (ESQ)

9. Exercise Protocol

  1. Participants will cycle on a stationary bike for 90-minutes at a pre-determined intensities corresponding to workloads of 4W/kg and 8 W/kg, as determined by VO2max test. Specifically, the participant will complete 3, 30-minute cycles consisting of 20-minutes at 4 W/kg and 10-minutes at 8 W/kg. Participants will be asked that they not drink water during the trial, but water will be available if participants want it.
  2. HR and Tc will be continuously monitored throughout exercise
  3. At every 10 minutes, the following measures will be collected and recorded:

i. HR ii. Tc iii. RPE iv. TCS v. Room Temperature and Humidity vi. Visual Analogue Scale for Fatigue (VAS-F) d. At the end of each 30-minute cycle, participants will complete the CWST while cycling.

e. During minutes 15-25 of each 30-minute cycle (the last 5-min at 4 W/kg and the first 5-min at 8 W/kg), the participant will be hooked up to the same mouthpiece and nose clip used for baseline aerobic testing. This will be used to calculate estimated metabolic rate during the trial.

10. Post-Exercise Heat Measures (in heat chamber):

  1. After completing the 90-minute exercise protocol, participants will remain seated in the chamber for 10-minutes
  2. Starting at the 5-minute post-exercise mark, the following will be collected:

i. HR ii. Tc iii. RPE iv. TCS v. CWST vi. Room Temperature and Humidity vii. Visual Analogue Scale for Fatigue (VAS-F) viii. POMS ix. GIQ x. ESQ xi. Blood Pressure xii. I-STAT capillary blood measurement

11.Post-Exercise Hydration Assessments

  1. Participants will provide a urine sample to reassess hydration using USG, urine flow rate, and store urine for future analyses (as described above).
  2. They will also obtain a second nude body weight following the same procedure as pre-exercise.
  3. They will also provide a urine sample.
  4. Following this, participants will be given a standardized volume of water (500 mL for individuals \< 75 kg, 1 L for individuals ≥75kg) to ingest by the end of the hour following the end of the exercise trial.
  5. During this time, participants will be allowed to change clothing

    12. After providing urine and changing, participants will complete all cognition assessments.

    13. 1-Hour Post-Exercise Hydration Assessments

a. Another blood collection measurement will be conducted. b. Participants will provide a urine sample to reassess hydration using USG, urine flow rate, and store urine for future analyses.

14. Subjects will then be scheduled for their second exercise visit (following 28-day washout period- 21 day washout then 7 days of supplementation).

03

Conditions studied

  • Acute Kidney Injury
  • Exertional Heat Illness

Keywords

  • acute kidney injury
  • creatine monohydrate
  • exertional heat stress
  • cognition
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age range: 18-45 years old
  • Physical Activity Level: Classified as 'active' using the criteria of engaging in planned exercise at least 3x/week, for a minimum of 30 minutes per session, over the past 3 months
  • Aerobic Fitness Level: Subjects must have an aerobic fitness classification of at least 'good' per American College of Sports Medicine (ACSM) criteria and assessed via maximal oxygen uptake test
  • Health Status: Free of any known cardiovascular, metabolic, renal, or neurologic conditions.
  • Physical Limitations: Indicates no physical limitations to cycling for \~ 90 minutes
  • Supplementation: Reports no use of creatine within the past 4 weeks
  • Recent Illness: Reports no presence of illness, vomiting, or diarrhea in the previous three days.

Exclusion criteria

Exclusion Criteria:

  • Known allergy to creatine or maltodextrin.
  • History of adverse heat-related events (e.g., heat exhaustion, heat stroke, severe dehydration requiring medical intervention)
  • Reports use of medications or supplements that may interfere with thermoregulation, heart rate, kidney injury or blood pressure responses during exercise (e.g. NSAID)
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Creatine Monohydrate

    Participants will ingest 20 grams per day of creatine monohydrate for 7 days, then 1 day of 5 grams before the exertional heat trial.

    Dietary Supplement: Creatine Monohydrate

  • Placebo comparator
    Placebo (Maltodextrin)

    Participants will ingest 20 grams per day of maltodextrin for 7 days, then 1 day of 5 grams before the exertional heat trial.

    Dietary Supplement: Maltodextrin (Placebo)

Interventions

  • Dietary supplementCreatine Monohydrate

    20 grams per day of creatine monohydrate for 7 days, followed by 1 day of 5 grams of supplementation.

  • Dietary supplementMaltodextrin (Placebo)

    Participants will ingest 20 grams per day for 7 days, followed by 1 day of 5 grams.

06

What researchers measure

Primary outcomes

  1. Change in Urine Biomarker of Acute Kidney Injury Risk from Creatine Use Prior to Exercise in the Heat (The mathematical product of IGBFP7 and TIMP-2 [IGFBP7 x TIMP-2; NephroCheck®])

    Concentrations of both IGBFP7 and TIMP-2 will be measured in the urine. The mathematical product of these values (IGFBP7 x TIMP-2) will then be calculated and reported for each time point.

    Time frame: Change in urinary IGBP7 x TIMP-2 from immediately before exercise in the heat to 1 hour after exercise in the heat.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Mar 2027, 12 months later.

Of 251 non-industry interventional studies with no phase under Acute Kidney Injury, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 44. This study's planned 12 months is below that.

Counting every sponsor, half of 269 studies reached it within 26 months; a quarter within 12 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2026
First posted
Mar 16, 2026
StartEst.
Mar 12, 2026
Primary completionEst.
Mar 2027
CompletionEst.
May 2027
Last update
Mar 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07472426
Lead sponsor
University of Northern Iowa
Responsible party
Jon Specht (Assistant Professor, University of Northern Iowa) — Principal investigator
First posted
Mar 16, 2026
Start date
Mar 12, 2026 (estimated)
Primary completion
Mar 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Mar 16, 2026

Study contacts

Assistant Professor, PhD
Contact
jonathan.specht@uni.edu
5635137807

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Creatine monohydrate

Start the discussion